Our vision: Harnessing the immune system’s power to turn science into survival. Data Privacy: https://xitter.cf/t.co/ZHMXceTxRG Imprint: https://xitter.cf/t.co/VNRPNHg7b0
Mainz, Germany
Joined November 2018
- Tweets319
- Following163
- Followers79.2K
- Likes45
🎗 Not every breast cancer journey looks the same.
For people living with metastatic breast cancer, treatment can become part of everyday life and options may change over time.
Here are 5 reasons why continued research matters, during #BreastCancerAwarenessMonth and every day.
Lung cancer is not one disease.
Following #WCLC26, Dr.@StephenVLiu reflects on the complexity of lung cancer, how our understanding has evolved and why different strategies need to be explored to address the needs that remain.
Watch 👇
#LungCancer #CancerResearch
📢 Oncology news in 2L+ sqNSCLC: We presented the first median overall survival data from the PRESERVE-003 Phase 3 trial for a chemotherapy-free CTLA-4-targeting immunotherapy in 2L+ squamous non-small cell lung cancer.
🔗 Learn more: bit.ly/4h5DjqL
#LungCancer #WCLC26
We are excited to share new clinical data from our diversified lung cancer pipeline, including the first combination data for any PD-(L)1xVEGF bispecific plus a B7H3 ADC in lung cancer.
🔗 Learn more: bit.ly/4gaKY7W
#LungCancer #Oncology #WCLC26 #BioNTech
📢 𝗤𝟮 𝟮𝟬𝟮𝟲 𝗲𝗮𝗿𝗻𝗶𝗻𝗴𝘀 𝗿𝗲𝘀𝘂𝗹𝘁𝘀 𝗮𝗻𝗱 𝗰𝗼𝗺𝗽𝗮𝗻𝘆 𝘂𝗽𝗱𝗮𝘁𝗲
𝗟𝗶𝗻𝗸 𝘁𝗼 𝗽𝗿𝗲𝘀𝘀 𝗿𝗲𝗹𝗲𝗮𝘀𝗲 𝗮𝗻𝗱 𝗳𝗼𝗿𝘄𝗮𝗿𝗱-𝗹𝗼𝗼𝗸𝗶𝗻𝗴 𝘀𝘁𝗮𝘁𝗲𝗺𝗲𝗻𝘁𝘀:
bit.ly/4h9thXn
We are building for the many within lung cancer. Through 16+ clinical trials, we are pursuing innovative therapeutic approaches across subtypes and biomarkers to advance progress where patients still need more.
Explore the many: bit.ly/3TuyK13
#WorldLungCancerDay
At #SGOAM26 we are presenting data from the largest trial to date to report results for a HER2-targeted ADC in recurrent HER2-expressing endometrial cancer.
Read more: bit.ly/4voJn42
#BioNTech #WomensCancer #GynecologicOncology
Tomorrow at #ELCC26, Dr. Kai He will share data from stage 1 of the global Phase 3 PRESERVE-003 clinical trial evaluating a tumor microenvironment-selective regulatory T cell depletion candidate targeting CTLA-4 in second-line or later therapy of squamous NSCLC.
Tomorrow at #ELCC26, @bensolomon1 will share the global Phase 2/3 ROSETTA Lung-02 trial design evaluating a PD-L1xVEGF-A bispecific immunomodulator plus chemotherapy in first-line non-small cell lung cancer (NSCLC).The candidate is being developed by BioNTech and @bmsnews
At the #ELCC2026, we will present new clinical data from our late-stage portfolio across various #lungcancer subtypes and lines of treatment, reinforcing the transformative potential of our treatment approaches in this critical area.
👉bit.ly/3NEw5zp
#nsclc #esclc
